We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

RHINOSECTAN®

0

News on NOVENTURE participation in 2018 EAACI in Munich

Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI - European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018. Noventure participated in this congress to announce its presence in the allergy field thanks to its medical device RHINOSECTAN® intended to control and prevent symptoms of rhinitis and rhinosinusitis, especially those of allergic origin. EAACI is the Europe’s largest medical association in the field of allergy and clinical immunology and it offers a unique chance to learn about latest discovery as it gathers KOLs from around the world.

Read more

Rhinosectan® Launched In Spain

We are pleased to announce the launch of Rhinosectan® in its first market, Spain. The product is commercialized under the brand Rinonet/Rhinosectan®, is distributed by Laboratorios SALVAT S.A.and has been available as 15 ml solution for intranasal application in pharmacies across Spain since May.

Read more

Let's meet in..

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more

2019, Feb 25

euroPLX 69 London

Read more

2019, Mar 15

EAU 19

Read more